» Articles » PMID: 7102703

Influence of Hemodialysis on Acyclovir Pharmacokinetics in Patients with Chronic Renal Failure

Overview
Journal Am J Med
Specialty General Medicine
Date 1982 Jul 20
PMID 7102703
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetic disposition of acyclovir was studied in six patients with chronic renal failure (CRF) and anuria. At the end of a one-hour intravenous infusion (2.5 mg/kg), the mean peak acyclovir plasma level (+/- SD), determined by radioimmunoassay, was 37.5 +/- 24.2 microM (8.4 +/- 5.4 microgram/ml), twice the level found at this dose in patients with normal renal function (NRF). In the CRF volunteers, significant plasma levels (3.0 +/- 1.4 microM) persisted at 47 hours after drug administration (before hemodialysis) whereas in the NRF patients levels dropped to less than 1 microM by 11 hours. Hemodialysis was started 47 hours after infusion and was continued for six hours. The pre-dialysis plasma drug level was reduced by 61.5 percent at 0.25 to 1.5 hours after the end of dialysis. The mean plasma t 1/2 during dialysis of 5.4 hours, the extraction ratio of 0.44, and the dialysis clearance for plasma of 113 ml/min indicate that acyclovir is efficiently removed by hemodialysis. One-half the suggested intravenous dose for a particular indication can be given every 24 hours and a similar replacement dose should be given after each dialysis.

Citing Articles

An Unusual Neurological Syndrome in a Haemodialysis Patient.

Jose N, Jayaprakash V, Deiva A, Jayakumar M Indian J Nephrol. 2021; 31(3):293-295.

PMID: 34376947 PMC: 8330665. DOI: 10.4103/ijn.IJN_11_20.


A Unique Case of Valacyclovir Toxicity and Pseudobulbar Affect in a Patient On Peritoneal Dialysis.

Memon W, Rose E, Akram A, Simba B Cureus. 2021; 13(2):e13494.

PMID: 33777579 PMC: 7990347. DOI: 10.7759/cureus.13494.


Acyclovir Neurotoxicity in a Peritoneal Dialysis Patient: Report of a Case and Review of the Pharmacokinetics of Acyclovir.

Sadjadi S, Regmi S, Chau T Am J Case Rep. 2018; 19:1459-1462.

PMID: 30531673 PMC: 6298245. DOI: 10.12659/AJCR.911520.


The use of antiviral drugs during the neonatal period.

Whitley R Clin Perinatol. 2012; 39(1):69-81.

PMID: 22341538 PMC: 3290126. DOI: 10.1016/j.clp.2011.12.004.


Comparative pharmacokinetics of antiviral nucleoside analogues.

Morse G, Shelton M, ODonnell A Clin Pharmacokinet. 1993; 24(2):101-23.

PMID: 8453821 DOI: 10.2165/00003088-199324020-00002.